ATLANTA, Aug. 28, 2024 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (1) Defendants did not fully disclose the circumstances under which the Heart-1 trial would be halted; and (2) Defendants overstated the potential benefits of its proprietary LNP delivery system.
If you bought shares of Verve Therapeutics between August 9, 2022 and April 1, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/verve-therapeutics/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is October 28, 2024.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
- Jellystone Park Camp-Resorts near Columbus, Ohio, Port Huron, Michigan and in Warrens, Wisconsin Conjure up Halloween Fun - September 16, 2024
- Global Zirconia Based Dental Ceramics Market is Expected to Grow at a CAGR of 9.1% over the Forecast Period (2024 – 2034): A Report by TNR, The Niche Research - September 16, 2024
- Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - September 16, 2024
